Abstract
Newborn screening identifies patients with very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency with disease-specific acylcarnitine profiles. We here present a patient who died at 16 months during a gastrointestinal infection because of undiagnosed VLCADD. The primary acylcarnitine profile on newborn screening performed at 55 h of life revealed C14-acylcarnitine values and ratios within the 1st percentile VLCAD disease range and C12-acylcarnitine values and ratios within the 10th percentile disease range. The acylcarnitine cumulative percentiles in neonatal dried blood spots analyzed by tandem mass spectrometry have been obtained by participants of the Region 4 Stork collaborative project. A secondary screen was requested by the screening laboratory as a result of the initial screen and was normal on day 8 of life. With the initial acylcarnitines only within the 1st–10th percentile disease range, newborn screening for VLCAD deficiency was in the end considered normal. The most important lesson learned is that acylcarnitine profiles from healthy newborns during catabolism and VLCAD-deficient patients can in certain cases not be distinguished by any means. With a known high incidence of false positive cases for VLCADD on newborn screening, it finally remains unknown, whether forced anabolism in the first days of life may result in normal acylcarnitine profiles in VLCAD-deficient patients resulting in missed cases and false negatives on newborn screening. Our observations are of great significance since they demonstrate the limitations of acylcarnitine analysis as screening tool for VLCAD-deficiency.
Competing interests: None declared
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Arnold GL, Van Hove J, Freedenberg D et al (2009) A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency. Mol Genet Metab 96(3):85–90
Boneh A, Andresen BS, Gregersen N et al (2006) VLCAD deficiency: pitfalls in newborn screening and confirmation of diagnosis by mutation analysis. Mol Genet Metab 88(2):166–170
Ficicioglu C, Coughlin CR II, Bennett MJ et al (2010) Very long-chain acyl-CoA dehydrogenase deficiency in a patient with normal newborn screening by tandem mass spectrometry. J Pediatr 156(3):492–494
German AWMF Guidelines (2011) German AWMF guidelines for the confirmation diagnosis of metabolic diseases identified by newborn screening (guideline no 027/021). http://www.awmf.org. Accessed 11 July 2011
Liebig M, Schymik I, Mueller M et al (2006) Neonatal screening for very long-chain acyl-coA dehydrogenase deficiency: enzymatic and molecular evaluation of neonates with elevated C14:1-carnitine levels. Pediatrics 118(3):1065–1069
McGoey RR, Marble M (2011) Positive newborn screen in a normal infant of a mother with asymptomatic very long-chain acyl-CoA dehydrogenase deficiency. J Pediatr 158(6):1031–1032
McHugh DM, Cameron CA, Abdenur JE et al (2011) Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: a worldwide collaborative project. Genet Med 13(3):230–254
Schymik I, Liebig M, Mueller M et al (2006) Pitfalls of neonatal screening for very-long-chain acyl-CoA dehydrogenase deficiency using tandem mass spectrometry. J Pediatr 149(1):128–130
Spiekerkoetter U, Huener G, Baykal T et al (2003) Silent and symptomatic primary carnitine deficiency within the same family due to identical mutations in the organic cation/carnitine transporter OCTN2. J Inherit Metab Dis 26(6):613–615
Spiekerkoetter U, Haussmann U, Mueller M et al (2010) Tandem mass spectrometry screening for very long-chain acyl-CoA dehydrogenase deficiency: the value of second-tier enzyme testing. J Pediatr 157(4):668–673
Wilcken B (2010) Fatty acid oxidation disorders: outcome and long-term prognosis. J Inherit Metab Dis 33(5):501–506
Acknowledgments
We thank the newborn screening laboratory for provision of all screening parameters in order to learn from this unfortunate course of disease. The authors and the screening laboratory agree that the identity of the screening laboratory should remain anonymous.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Additional information
Communicated by: Bridget Wilcken
Take-Home Message
Take-Home Message
Acylcarnitine profiles from healthy newborns during catabolism and VLCAD-deficient patients can in certain cases not be distinguished, demonstrating the limitations of acylcarnitine analysis as the screening tool for VLCAD-deficiency.
Rights and permissions
Copyright information
© 2012 SSIEM and Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Spiekerkoetter, U., Mueller, M., Sturm, M., Hofmann, M., Schneider, D.T. (2012). Lethal Undiagnosed Very Long-Chain Acyl-CoA Dehydrogenase Deficiency with Mild C14-Acylcarnitine Abnormalities on Newborn Screening. In: JIMD Reports - Case and Research Reports, 2012/3. JIMD Reports, vol 6. Springer, Berlin, Heidelberg. https://doi.org/10.1007/8904_2012_129
Download citation
DOI: https://doi.org/10.1007/8904_2012_129
Received:
Revised:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-28128-0
Online ISBN: 978-3-642-28129-7
eBook Packages: MedicineMedicine (R0)